BDTX - Black Diamond Therapeutics Inc

BDTX - Black Diamond Therapeutics Inc

https://www.blackdiamondtherapeutics.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Is BDTX's Cash balance Enough to Successfully Develop Its NSCLC Drug?

Zacks Commentary • 3 days, 6 hours ago • score: 0.24

Black Diamond sharpens focus on silevertinib after outlicensing BDTX-4933, cutting costs, and securing cash runway into late 2027.

BDTX Stock Surges 51.1% in Six Months: Is There More Room for Growth?

Zacks Commentary • 1 week, 3 days ago • score: 0.28

Black Diamond shines with a 51.1% stock surge, fueled by silevertinib's progress and pipeline momentum in oncology.

Is the Recent Pipeline Progress on its NSCLC Drug Enough for BDTX?

Zacks Commentary • 1 week, 4 days ago • score: 0.26

Black Diamond focuses on silevertinib for NSCLC and GBM, with key trial readouts due in late 2025 and FDA feedback expected in 2026.

Black Diamond ( BDTX ) Q2 Loss Narrows 47%

Motley Fool • 1 month, 1 week ago • score: 0.42

Black Diamond Therapeutics ( NASDAQ:BDTX ) , a biotechnology developer focused on precision cancer therapies, reported its financial results for the second quarter of fiscal 2025 on August 7, 2025. The most notable takeaway was a marked improvement in financial efficiency: net loss per share ( ...

Black Diamond Therapeutics Inks Licensing Pact With French Pharma Firm Servier For Its Early-Stage Cancer Drug Worth Over $700 Million - Black Diamond Therapeutic ( NASDAQ:BDTX )

Benzinga • 5 months, 3 weeks ago • score: 0.21

Servier will lead the development activities and the worldwide commercialization of BDTX-4933 across multiple indications. Currently, in Phase 1 development, BDTX-4933 is designed to target RAS and RAF alterations in solid tumors.

Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy

GlobeNewswire • 5 months, 3 weeks ago • score: 0.19

SURESNES, France and CAMBRIDGE, Mass., March 19, 2025 ( GLOBE NEWSWIRE ) -- Servier, an independent global pharmaceutical group governed by a non-profit foundation, and Black Diamond Therapeutics, Inc. ( Nasdaq: BDTX ) , a clinical-stage oncology company developing MasterKey therapies that ...

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire • 10 months, 2 weeks ago • score: -0.19

CAMBRIDGE, Mass., Nov. 01, 2024 ( GLOBE NEWSWIRE ) -- Black Diamond Therapeutics, Inc. ( Nasdaq: BDTX ) , a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Black Diamond Therapeutics, Inc., a biotechnology company, discovers and develops small molecule tumor agnostic therapies. The company is headquartered in Cambridge, Massachusetts.

52W High

$6.33

52W Low

$1.20

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

2.94

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

12.25

Forward P/E (<15 better)

8.33

EV/EBITDA (<8 favorable)

8.97

EV/Revenue (<3 favorable)

0.65

P/S (TTM) (<3 favorable)

2.39

P/B (<3 favorable)

1.26

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

0.63%

Institutions (25–75% balanced)

78.83%

Shares Outstanding

56,935,000

Float

39,244,300

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

70,000,000

Gross Profit (TTM)

70,000,000

EPS (TTM)

0.24

Profit Margin (>10% good)

0.21%

Operating Margin (TTM) (higher better)

0.11%

ROE (TTM) (>15% strong)

0.12%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

0.1698

Previous

0.1617

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025